Recent publications · Crossref
5 total works indexed
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias:
<i>lipid modification to reduce cardiovascular risk</i>
· 2019 · cited 7,612x
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
· 2012 · cited 4,392x
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
· 2019 · cited 2,530x
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
· 2009 · cited 1,917x
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial